Phase 2 N=2 Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer
Urothelial Carcinoma of the Bladder
Primary: Number of Participants With Adverse Events — 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=159 Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients
Heart Failure · Cardiomyopathy · Ventricular Dysfunction
Primary: Number of Temporary Weans From LVAD Support Tolerated — 0.61; 0.58 number of weans
Phase 2 N=59 Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients
Psoriasis
Primary: Percentage of Participants With Palmoplantar (pp) Pustular Psoriasis Area and Severity Index 50 (PASI) (ppPASI50) at Week 16 — 31.6; 31.6; 23.8 Percentage of…
Phase 2 N=72 A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Primary: Overall Response Rate (ORR) as Assessed by the Investigator Using the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 Criteria — 78.6 percentage of…
Phase 2 N=44 A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation
Pulmonary Disease, Chronic Obstructive
Primary: Change in Messenger Ribonucleic Acid (mRNA) Transcriptome in Induced Sputum After 12, 28 and 84 Days of Treatment (Selected Probe Sets With Fold Change >1.5 or <-1.5 and…
Phase 2 N=60 Study to Evaluate a HIV Drug for the Treatment of HIV Infection
Infection, Human Immunodeficiency Virus · HIV Infections
Primary: Change in Plasma Log10 HIV-1 Ribonucleic Acid (RNA) Levels From Baseline to Day 11 — -0.138; -0.567; -0.889; -1.279 Log10 copies per milliliter (c/mL)
Phase 2 N=24 An 8-Week Refractory Chronic Cough Study (MK-7264-021)
Refractory Chronic Cough
Primary: Change From Baseline in Awake Cough Frequency After 8 Weeks of Treatment. — -7.5; -16.9; -18.5; 0.3 Coughs/hour
Phase 2 N=308 A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery
VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery
Primary: Number of Participants With Treatment-emergent Bleeding Events (Clinical Events Committee [CEC]- Adjudicated) — 2; 0; 5; 1 Participants
Phase 2 N=84 Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung
Adenocarcinoma · Non-small Cell Lung Cancer
Primary: Overall Response Rate (ORR) — 27.7 percentage of participants
Phase 2 N=35 Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT
Diffuse Large B-cell Lymphoma
Primary: Overall Response Rate (ORR) at the End of the Induction Phase — 17.1 percentage of participants
Phase 2 N=47 Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
Aggressive Non-Hodgkin Lymphoma · Blasts Under 5 Percent of Bone Marrow Nucleated Cells · Chronic Lymphocytic Leukemia
Primary: Number of Patients With Grade III-IV Acute Graft-versus-host Disease (GVHD) Post-transplant — 2; 0; 0 Participants
Phase 2 N=39 Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer (NSCLC)
Primary: Therapeutic Efficacy of Anti-CTLA-4 mAb and Concurrent Local RT in NSCLC Patients With Metastatic Disease. — 7 Participants
Phase 2 N=10 Testosterone Treatment for Multiple Sclerosis
Multiple Sclerosis
Primary: Whole Brain Atrophy Rate — .82 percent change in brain volume — p=<0.05
Phase 2 N=95 Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
Primary: Objective Response Rate (ORR) — 1; 11; 7; 8 Participants
Phase 2 N=20 Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia
Critical Limb Ischemia
Primary: Reintervention, Above Ankle Amputation and Restenosis (RAS) — 7; 4 Participants